These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16139732)

  • 1. Dopamine transporter in attention-deficit hyperactivity disorder normalizes after cessation of methylphenidate.
    Feron FJ; Hendriksen JG; van Kroonenburgh MJ; Blom-Coenjaerts C; Kessels AG; Jolles J; Weber WE; Vles JS
    Pediatr Neurol; 2005 Sep; 33(3):179-83. PubMed ID: 16139732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder--a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study.
    Szobot CM; Shih MC; Schaefer T; Júnior N; Hoexter MQ; Fu YK; Pechansky F; Bressan RA; Rohde LA
    Neuroimage; 2008 Apr; 40(3):1195-201. PubMed ID: 18282769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD).
    Vles JS; Feron FJ; Hendriksen JG; Jolles J; van Kroonenburgh MJ; Weber WE
    Neuropediatrics; 2003 Apr; 34(2):77-80. PubMed ID: 12776228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography.
    Krause KH; Dresel SH; Krause J; Kung HF; Tatsch K
    Neurosci Lett; 2000 May; 285(2):107-10. PubMed ID: 10793238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder.
    Wang GJ; Volkow ND; Wigal T; Kollins SH; Newcorn JH; Telang F; Logan J; Jayne M; Wong CT; Han H; Fowler JS; Zhu W; Swanson JM
    PLoS One; 2013; 8(5):e63023. PubMed ID: 23696790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD.
    Krause J; la Fougere C; Krause KH; Ackenheil M; Dresel SH
    Eur Arch Psychiatry Clin Neurosci; 2005 Dec; 255(6):428-31. PubMed ID: 16091862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment.
    del Campo N; Fryer TD; Hong YT; Smith R; Brichard L; Acosta-Cabronero J; Chamberlain SR; Tait R; Izquierdo D; Regenthal R; Dowson J; Suckling J; Baron JC; Aigbirhio FI; Robbins TW; Sahakian BJ; Müller U
    Brain; 2013 Nov; 136(Pt 11):3252-70. PubMed ID: 24163364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vivo quantification of dose-dependent dopamine transporter blockade in the rat striatum with small animal SPECT.
    Nikolaus S; Antke C; Beu M; Kley K; Larisch R; Wirrwar A; Müller HW
    Nucl Med Commun; 2007 Mar; 28(3):207-13. PubMed ID: 17264780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention deficit/hyperactivity disorder: is there a correlation between dopamine transporter density and cerebral blood flow?
    da Silva N; Szobot CM; Anselmi CE; Jackowski AP; Chi SM; Hoexter MQ; Anselmi OE; Pechansky F; Bressan RA; Rohde LA
    Clin Nucl Med; 2011 Aug; 36(8):656-60. PubMed ID: 21716015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type.
    Roessner V; Sagvolden T; Dasbanerjee T; Middleton FA; Faraone SV; Walaas SI; Becker A; Rothenberger A; Bock N
    Neuroscience; 2010 Jun; 167(4):1183-91. PubMed ID: 20211696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study.
    Rohde LA; Roman T; Szobot C; Cunha RD; Hutz MH; Biederman J
    Synapse; 2003 May; 48(2):87-9. PubMed ID: 12619042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Searching for a neurobiological basis for self-medication theory in ADHD comorbid with substance use disorders: an in vivo study of dopamine transporters using (99m)Tc-TRODAT-1 SPECT.
    Silva N; Szobot CM; Shih MC; Hoexter MQ; Anselmi CE; Pechansky F; Bressan RA; Rohde LA
    Clin Nucl Med; 2014 Feb; 39(2):e129-34. PubMed ID: 23856832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.
    Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
    Biol Psychiatry; 2005 Feb; 57(3):229-38. PubMed ID: 15691523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder.
    Volkow ND; Wang GJ; Newcorn J; Telang F; Solanto MV; Fowler JS; Logan J; Ma Y; Schulz K; Pradhan K; Wong C; Swanson JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):932-40. PubMed ID: 17679638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder.
    Rosa-Neto P; Lou HC; Cumming P; Pryds O; Karrebaek H; Lunding J; Gjedde A
    Neuroimage; 2005 Apr; 25(3):868-76. PubMed ID: 15808987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.
    Capp PK; Pearl PL; Conlon C
    Expert Rev Neurother; 2005 May; 5(3):325-31. PubMed ID: 15938665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate.
    Cheon KA; Ryu YH; Kim JW; Cho DY
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):95-101. PubMed ID: 15572278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder.
    Krause J
    Expert Rev Neurother; 2008 Apr; 8(4):611-25. PubMed ID: 18416663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive Improvement of Attention and Inhibition in the Late Afternoon in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Treated With Osmotic-Release Oral System Methylphenidate.
    Slama H; Fery P; Verheulpen D; Vanzeveren N; Van Bogaert P
    J Child Neurol; 2015 Jul; 30(8):1000-9. PubMed ID: 25296928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder.
    Cheon KA; Ryu YH; Kim YK; Namkoong K; Kim CH; Lee JD
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):306-11. PubMed ID: 12552351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.